Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Prostate Cancer

  Free Subscription

Articles published in PLoS Med

Retrieve available abstracts of 6 articles:
HTML format

Single Articles

    February 2020
  1. FREDSOE J, Koetsenruyter J, Vedsted P, Kirkegaard P, et al
    The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial.
    PLoS Med. 2020;17:e1003033.
    PubMed     Abstract available

    December 2019
  2. CALLENDER T, Emberton M, Morris S, Eeles R, et al
    Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
    PLoS Med. 2019;16:e1002998.
    PubMed     Abstract available

    October 2019
  3. BJERRE ED, Petersen TH, Jorgensen AB, Johansen C, et al
    Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial.
    PLoS Med. 2019;16:e1002936.
    PubMed     Abstract available

    July 2019
  4. GROSSET AA, Ouellet V, Caron C, Fragoso G, et al
    Validation of the prognostic value of NF-kappaB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.
    PLoS Med. 2019;16:e1002847.
    PubMed     Abstract available

    June 2019
  5. JAMBOR I, Verho J, Ettala O, Knaapila J, et al
    Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial.
    PLoS Med. 2019;16:e1002813.
    PubMed     Abstract available

    March 2019
  6. THURTLE DR, Greenberg DC, Lee LS, Huang HH, et al
    Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model.
    PLoS Med. 2019;16:e1002758.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.